Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective

Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient’s immune system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of action leads to durable responses and prolonged survival in some patients. However, providing robust evidence of the lon...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Quinn, Casey, Garrison, Louis P, Pownell, Anja K, Atkins, Michael B, de Pouvourville, Gérard, Harrington, Kevin, Ascierto, Paolo Antonio, McEwan, Phil, Wagner, Samuel, Borrill, John, Wu, Elise
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2020
Soggetti:
Position Article and Guidelines
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7359062/
https://ncbi.nlm.nih.gov/pubmed/32661115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000648
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi